Hif-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention

Current Molecular Pharmacology

Volumn 4, Issue 1, 2011, Pages 62-77

  Monti, Elena ^a   Gariboldi, Marzia B ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Apoptosis; Chemoprevention; Drug resistance; HIF 1 (Hypoxia Inducible Factor 1); Hypoxia; Microenvironment; Tumorigenesis

Indexed keywords

2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ACRIFLAVINE; ANTHRACYCLINE; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CORTICOSTEROID; DAUNORUBICIN; DOXORUBICIN; ECHINOMYCIN; EPIPODOPHYLLOTOXIN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; NSC 13502; NUTLIN 3; RESVERATROL; SALAZOSULFAPYRIDINE; STAT3 PROTEIN; SUMO PROTEIN; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; VINCA ALKALOID; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHEMOSENSITIZATION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYDROXYLATION; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; RESPIRATORY CHAIN; SUMOYLATION; TUMOR SUPPRESSOR GENE;

EID: 78650878686     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211104010062     Document Type: Article

References (186)

1. Harris, A. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2, 38-47
2. Wiesener, M.; Jürgensen, J.; Rosenberger, C.; Scholze, C.; Hörstrup, J.; Warnecke, C.; Mandriota, S.; Bechmann, I.; Frei, U.; Pugh, C.; Ratcliffe, P.; Bachmann, S.; Maxwell, P.; Eckardt, K. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J., 2003, 17, 271-273
3. Semenza, G.; Wang, G. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 1992, 12, 5447-5454
4. Wang, G.; Jiang, B.; Rue, E.; Semenza, G. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Pro.c Nat.l Acad. Sci. USA., 1995, 92, 5510-5514
5. Tian, H.; McKnight, S.; Russell, D. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev., 1997, 11, 72-82
6. Makino, Y.; Cao, R.; Svensson, K.; Bertilsson, G.; Asman, M.; Tanaka, H.; Cao, Y.; Berkenstam, A.; Poellinger, L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature, 2001, 414, 550-554
7. Bruick, R.; McKnight, S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001, 294, 1337-1340
8. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem., 1997, 272, 22642-22647
9. Jeong, J.; Bae, M.; Ahn, M.; Kim, S.; Sohn, T.; Bae, M.; Yoo, M.; Song, E.; Lee, K.; Kim, K. Regulation and destabilization of HIF1alpha by ARD1-mediated acetylation. Cell, 2002, 111, 709-720
10. Arnesen, T.; Kong, X.; Evjenth, R.; Gromyko, D.; Varhaug, J.; Lin, Z.; Sang, N.; Caro, J.; Lillehaug, J. Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS Lett., 2005, 579, 6428-6432
11. Bilton, R.; Mazure, N.; Trottier, E.; Hattab, M.; Déry, M.; Richard, D.; Pouysségur, J.; Brahimi-Horn, M. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J. Biol. Chem., 2005, 280, 31132-31140
12. Lee, M.; Lee, S.; Kim, S.; Kim, B.; Jung, B.; Seo, J.; Park, J.; Choi, J.; Yim, S.; Lee, M.; Park, J.; Yoo, J.; Kim, J.; Lee, S.; Kim, H.; Ryeom, S.; Kim, K.; Oh, G. Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis. J. Natl. Cancer Inst., 2010, 102, 426-442
13. Lando, D.; Peet, D.; Gorman, J.; Whelan, D.; Whitelaw, M.; Bruick, R. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev., 2002, 16, 1466-1471
14. Koivunen, P.; Hirsilä, M.; Günzler, V.; Kivirikko, K.; Myllyharju, J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4- hydroxylases. J. Biol. Chem., 2004, 279, 9899-9904
15. Dayan, F.; Roux, D.; Brahimi-Horn, M.; Pouyssegur, J.; Mazure, N. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res., 2006, 66, 3688-3698
16. Chandel, N.; McClintock, D.; Feliciano, C.; Wood, T.; Melendez, J.; Rodriguez, A.; Schumacker, P. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J. Biol. Chem., 2000, 275, 25130-25138
17. Guzy, R.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K.; Simon, M.; Hammerling, U.; Schumacker, P. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab., 2005, 1, 401-408
18. Mansfield, K.; Guzy, R.; Pan, Y.; Young, R.; Cash, T.; Schumacker, P.; Simon, M. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab., 2005, 1, 393-399
19. Klimova, T.; Chandel, N. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ., 2008, 15, 660-666
20. Shao, R.; Zhang, F.; Tian, F.; Anders Friberg, P.; Wang, X.; Sjöland, H.; Billig, H. Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo. FEBS Lett., 2004, 569, 293-300
21. Carbia-Nagashima, A.; Gerez, J.; Perez-Castro, C.; Paez-Pereda, M.; Silberstein, S.; Stalla, G.; Holsboer, F.; Arzt, E. Cell, 2007, 131, 309-323
22. Bae, S.; Jeong, J.; Park, J.; Kim, S.; Bae, M.; Choi, S.; Kim, K. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem. Biophys. Res. Commun., 2004, 324, 394-400
23. Cheng, J.; Kang, X.; Zhang, S.; Yeh, E. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 2007, 131, 584-595
24. Kim, Y.; Choi, C.; Lee, S.; Conti, M.; Kim, Y. Homeodomaininteracting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem., 1998, 273, 25875-25879
25. D'Orazi, G.; Cecchinelli, B.; Bruno, T.; Manni, I.; Higashimoto, Y.; Saito, S.; Gostissa, M.; Coen, S.; Marchetti, A.; Del Sal, G.; Piaggio, G.; Fanciulli, M.; Appella, E.; Soddu, S. Homeodomaininteracting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell. Biol., 2002, 4, 11-9
26. Puca, R.; Nardinocchi, L.; Givol, D.; D'Orazi, G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene, 2010, 29(31), 4378-4387
27. Calzado, M.; Renner, F.; Roscic, A.; Schmitz, M. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle, 2007, 6, 139-143
28. Nardinocchi, L.; Puca, R.; Guidolin, D.; Belloni, A.; Bossi, G.; Michiels, C.; Sacchi, A.; Onisto, M.; D'Orazi, G. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim. Biophys. Acta, 2009, 1793, 368-377
29. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M.; Simons, J.; Semenza, G. Modulation of hypoxiainducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 2000, 60, 1541-1545
30. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P.; Semenza, G. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol., 2001, 21, 3995-4004
31. Feldser, D.; Agani, F.; Iyer, N.; Pak, B.; Ferreira, G.; Semenza, G. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res., 1999, 59, 3915-3918
32. Slomiany, M.; Rosenzweig, S. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J. Pharmacol. Exp. Ther., 2006, 318, 666-675
33. Treins, C.; Giorgetti-Peraldi, S.; Murdaca, J.; Semenza, G.; Van Obberghen, E. J Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycindependent signaling pathway. J. Biol. Chem., 2002, 277, 27975-27981
34. Stiehl, D.; Jelkmann, W.; Wenger, R.; Hellwig-Bürgel, T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett., 2002, 512, 157-162
35. Hellwig-Bürgel, T.; Rutkowski, K.; Metzen, E.; Fandrey, J.; Jelkmann, W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood, 1999, 94, 1561-1567
36. Jiang, B.; Jiang, G.; Zheng, J.; Lu, Z.; Hunter, T.; Vogt, P. Phosphatidylinositol 3-kinase signaling controls levels of hypoxiainducible factor 1. Cell Growth Differ., 2001, 12, 363-369
37. Altomare, D.; Testa, J. Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005, 24, 7455-7464
38. Testa, J.; Tsichlis, P. AKT signaling in normal and malignant cells. Oncogene, 2005, 24, 7391-7393
39. Silvera, D.; Formenti, S.; Schneider, R. Translational control in cancer. Nat. Rev. Cancer, 2010, 10, 254-266
40. Fingar, D.; Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004, 23, 3151-3171
41. Pore, N.; Jiang, Z.; Shu, H.; Bernhard, E.; Kao, G.; Maity, A. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol. Cancer Res., 2006, 4, 471-479
42. Alvarez-Tejado, M.; Alfranca, A.; Aragonés, J.; Vara, A.; Landázuri, M.; del Peso, L. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J. Biol. Chem., 2002, 277, 13508-13517
43. Arsham, A.; Plas, D.; Thompson, C.; Simon, M. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem., 2002, 277, 15162-15170
44. Richard, D.; Berra, E.; Gothié, E.; Roux, D.; Pouysségur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxiainducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem., 1999, 274, 32631-32637
45. Sang, N.; Stiehl, D.; Bohensky, J.; Leshchinsky, I.; Srinivas, V.; Caro, J. MAPK signaling up-regulates the activity of hypoxiainducible factors by its effects on p300. J. Biol. Chem., 2003, 278, 14013-14019
46. Bárdos, J.; Ashcroft, M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta, 2005, 1755, 107-120
47. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 2004, 4, 97-105
48. Jung, J.; Kim, H.; Lee, C.; Shin, Y.; Kim, Y.; Kang, G.; Kim, T.; Juhnn, Y.; Kim, S.; Park, J.; Ye, S.; Chung, M. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp. Mol.Med., 2008, 40, 479-485
49. Niu, G.; Briggs, J.; Deng, J.; Ma, Y.; Lee, H.; Kortylewski, M.; Kujawski, M.; Kay, H.; Cress, W.; Jove, R.; Yu, H. Signal transducer and activator of transcription 3 is required for hypoxiainducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol. Cancer Res., 2008, 6, 1099-1105
50. Cascio, S.; D'Andrea, A.; Ferla, R.; Surmacz, E.; Gulotta, E.; Amodeo, V.; Bazan, V.; Gebbia, N.; Russo, A. miR-20b modulates VEGF expression by targeting HIF-1alpha and STAT3 in MCF-7 breast cancer cells. J. Cell Physiol., 2010, 224, 242-249
51. Cao, P.; Deng, Z.; Wan, M.; Huang, W.; Cramer, S.; Xu, J.; Lei, M.; Sui, G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF1beta. Mol. Cancer, 2010, 9, 108
52. Jung, J.; Lee, H.; Cho, I.; Chung, D.; Yoon, S.; Yang, Y.; Lee, J.; Choi, S.; Park, J.; Ye, S.; Chung, M. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J., 2005, 19, 1296-1298
53. Gariboldi, M.; Ravizza, R.; Monti, E. The IGFR1 inhibitor NVPAEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem. Pharmacol., 2010, 80, 455-462
54. Thomas, R.; Kim, M. A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. Prostate, 2009, 69, 263-275
55. Stoeltzing, O.; Liu, W.; Reinmuth, N.; Fan, F.; Parikh, A.; Bucana, C.; Evans, D.; Semenza, G.; Ellis, L. Regulation of hypoxiainducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol., 2003, 163, 1001-1011
56. Gunaratnam, L.; Morley, M.; Franovic, A.; de Paulsen, N.; Mekhail, K.; Parolin, D.; Nakamura, E.; Lorimer, I.; Lee, S. Hypoxia inducible factor activates the transforming growth factoralpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem., 2003, 278, 44966-44974
57. Zagzag, D.; Krishnamachary, B.; Yee, H.; Okuyama, H.; Chiriboga, L.; Ali, M.; Melamed, J.; Semenza, G. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res., 2005, 65, 6178-6188
58. Lau, C.; Yang, Z.; Ho, D.; Ng, M.; Yeoh, G.; Poon, R.; Fan, S. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res., 2009, 15, 3462-3471
59. Chen, C.; Pore, N.; Behrooz, A.; Ismail-Beigi, F.; Maity, A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem., 2001, 276, 9519-9525
60. Jiang, B.; Agani, F.; Passaniti, A.; Semenza, G. v-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res., 1997, 57, 5328-5335
61. Chan, D.; Sutphin, P.; Denko, N.; Giaccia, A. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor1alpha. J. Biol. Chem., 2002, 277, 40112-40117
62. Kumar, S.; Yu, H.; Edwards, R.; Chen, L.; Kazianis, S.; Brafford, P.; Acs, G.; Herlyn, M.; Xu, X. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res., 2007, 67, 3177-3184
63. Samuels, Y.; Diaz, L.A. Jr; Schmidt-Kittler, O.; Cummins, J.M.; DeLong, L.; Cheong, I.; Rago, C.; Huso, D.L.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7, 561-573
64. Carpten, J.D.; Faber, A.L.; Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter, G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y.-W.; Zeckner, D.J.; Tucker-Kellogg, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M.-H.T.; Blanchard, K.L.; Thomas, J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 2007, 448, 439-444
65. Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A.; Ryan, H.; Johnson, R.; Jefferson, A.; Stokoe, D.; Giaccia, A. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 2000, 14, 391-396
66. An, W.; Kanekal, M.; Simon, M.; Maltepe, E.; Blagosklonny, M.; Neckers, L. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature, 1998, 392, 405-408
67. Blagosklonny, M.; An, W.; Romanova, L.; Trepel, J.; Fojo, T.; Neckers, L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 1998, 273, 11995-11998
68. Ravi, R.; Mookerjee, B.; Bhujwalla, Z.M.; Sutter, C.H.; Artemov, D.; Zeng, Q.; Dillehay, L. E.; Madan, A.; Semenza, G.L.; Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev., 2000, 14, 34-44
69. Rius, J.; Guma, M.; Schachtrup, C.; Akassoglou, K.; Zinkernagel, A.S.; Nizet, V.; Johnson, R.S.; Haddad, G.G.; Karin, M. Nature, 2008, 453, 807-811
70. Whitesell, L.; Lindquist, S. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5, 761-772
71. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci., 2007, 1113, 202-216
72. Isaacs, J.; Jung, Y.; Mimnaugh, E.; Martinez, A.; Cuttitta, F.; Neckers, L. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem., 2002, 277, 29936-29944
73. Liu, Y.; Baek, J.; Zhang, H.; Diez, R.; Cole, R.; Semenza, G. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol. Cell, 2007, 25, 207-217
74. Liu, Y.; Semenza, G. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle, 2007, 6, 656-659
75. Kong, X.; Lin, Z.; Liang, D.; Fath, D.; Sang, N.; Caro, J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol., 2006, 26, 2019-2028
76. Makarova, O.; Makarov, E.; Lührmann, R. he 65 and 110 kDa SRrelated proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J., 2001, 20, 2553-2563
77. Koh, M.; Darnay, B.; Powis, G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell Biol., 2008, 28, 7081-7095
78. Koh, M.; Powis, G. HAF: the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle, 2009, 8, 1359-1366
79. Mole, D.; Blancher, C.; Copley, R.; Pollard, P.; Gleadle, J.; Ragoussis, J.; Ratcliffe, P. Genome-wide association of hypoxiainducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem., 2009, 284, 16767-16775
80. Krishnamachary, B.; Zagzag, D.; Nagasawa, H.; Rainey, K.; Okuyama, H.; Baek, J.; Semenza, G. Hypoxia-inducible factor-1dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res., 2006, 66, 2725-2731
81. Dang, C.; Kim, J.; Gao, P.; Yustein, J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer, 2008, 8, 51-56
82. Koshiji, M.; To, K.; Hammer, S.; Kumamoto, K.; Harris, A.; Modrich, P.; Huang, L. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell, 2005, 17, 793-803
83. To, K.K.W.; Sedelnikova, O.A.; Samons, M.; Bonner, W.M.; Huang, L.E. The phosphorylation status of PAS-B distinguishes HIF-1[alpha] from HIF-2[alpha] in NBS1 repression. EMBO J., 2006, 25, 4784-4794
84. Kulshreshtha, R.; Davuluri, R.; Calin, G.; Ivan, M. A microRNA component of the hypoxic response. Cell Death Differ., 2008, 15, 667-671
85. Huang, X.; Le, Q.; Giaccia, A. MiR-210-micromanager of the hypoxia pathway. Trends Mol. Med., 2010, 16, 230-237
86. Huang, X.; Ding, L.; Bennewith, K.; Tong, R.; Welford, S.; Ang, K.; Story, M.; Le, Q.; Giaccia, A. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell, 2009, 35, 856-867
87. Krieg, A.; Rankin, E.; Chan, D.; Razorenova, O.; Fernandez, S.; Giaccia, A. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol. Cell Biol., 2010, 30, 344-353
88. Xia, X.; Lemieux, M.; Li, W.; Carroll, J.; Brown, M.; Liu, X.; Kung, A. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA, 2009, 106, 4260-4265
89. Gatenby, R.; Gillies, R. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8, 56-61
90. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61, 759-767
91. Anderson, C.J.; Hoare, S.F.; Ashcroft, M.; Bilsland, A.E.; Keith, W.N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene, 2005, 25, 61-69
92. Coussens, M.; Davy, P.; Brown, L.; Foster, C.; Andrews, W.; Nagata, M.; Allsopp, R. RNAi screen for telomerase reverse transcriptase transcriptional regulators identifies HIF1{alpha} as critical for telomerase function in murine embryonic stem cells. Proc. Natl. Acad. Sci. USA, 2010, 107(31), 13842-7
93. Gatenby, R.; Gillies, R. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899
94. Denko, N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer, 2008, 8, 705-713
95. Zhang, H.; Bosch-Marce, M.; Shimoda, L.; Tan, Y.; Baek, J.; Wesley, J.; Gonzalez, F.; Semenza, G. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem., 2008, 283, 10892-10903
96. Wykoff, C.C.; Beasley, N.J.P.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. Hypoxiainducible Expression of Tumor-associated Carbonic Anhydrases. Cancer Res., 2000, 60, 7075-7083
97. Ceradini, D.J.; Kulkarni, A.R.; Callaghan, M.; Tepper, O.M.; Bastidas, N.; Kleinman, M. E.; Capla, J.M.; Galiano, R.D.; Levine, J.P.; Gurtner, G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med., 2004, 10, 858-864
98. Krishnamachary, B.; Berg-Dixon, S.; Kelly, B.; Agani, F.; Feldser, D.; Ferreira, G.; Iyer, N.; LaRusch, J.; Pak, B.; Taghavi, P.; Semenza, G.L. Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor 1. Cancer Res., 2003, 63, 1138-1143
99. Erler, J.T.; Bennewith, K.L.; Nicolau, M.; Dornhofer, N.; Kong, C.; Le, Q.-T.; Chi, J.-T.A.; Jeffrey, S.S.; Giaccia, A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 2006, 440, 1222-1226
100. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361
101. Pugh, C.W.; Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 2003, 9, 677-684
102. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol., 1996, 16, 4604-4613
103. Kaur, B.; Khwaja, F.; Severson, E.; Matheny, S.; Brat, D.; Van Meir, E. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro. Oncol., 2005, 7, 134-153
104. Gerber, H.; Condorelli, F.; Park, J.; Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem., 1997, 272, 23659-23667
105. Semenza, G. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 2010, 29, 625-634
106. Wakisaka, N.; Kondo, S.; Yoshizaki, T.; Murono, S.; Furukawa, M.; Pagano, J. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol. Cell Biol., 2004, 24, 5223-5234
107. Nakamura, M.; Bodily, J.; Beglin, M.; Kyo, S.; Inoue, M.; Laimins, L. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology, 2009, 387, 442-448
108. Cai, Q.; Murakami, M.; Si, H.; Robertson, E. A potential alphahelix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J. Virol., 2007, 81, 10413-10423
109. Zhong, H.; De Marzo, A.; Laughner, E.; Lim, M.; Hilton, D.; Zagzag, D.; Buechler, P.; Isaacs, W.; Semenza, G.; Simons, J. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res., 1999, 59, 5830-5835
110. Mabjeesh, N.; Amir, S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol., 2007, 22, 559-572
111. Semenza, G. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 2007, 12, 853-859
112. Semenza, G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3, 721-32
113. Cosse, J.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem., 2008, 8, 790-797
114. Unruh, A.; Ressel, A.; Mohamed, H.; Johnson, R.; Nadrowitz, R.; Richter, E.; Katschinski, D.; Wenger, R. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene, 2003, 22, 3213-3220
115. Comerford, K.; Wallace, T.; Karhausen, J.; Louis, N.; Montalto, M.; Colgan, S. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res., 2002, 62, 3387-3394
116. Krishnamurthy, P.; Ross, D.; Nakanishi, T.; Bailey-Dell, K.; Zhou, S.; Mercer, K.; Sarkadi, B.; Sorrentino, B.; Schuetz, J. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem., 2004, 279, 24218-24225
117. Riganti, C.; Doublier, S.; Viarisio, D.; Miraglia, E.; Pescarmona, G.; Ghigo, D.; Bosia, A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br. J. Pharmacol., 2009, 156, 1054-1066
118. Hussein, D.; Estlin, E.; Dive, C.; Makin, G. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol. Cancer Ther., 2006, 5, 2241-2250
119. Zeng, L.; Kizaka-Kondoh, S.; Itasaka, S.; Xie, X.; Inoue, M.; Tanimoto, K.; Shibuya, K.; Hiraoka, M. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci., 2007, 98, 1394-1401
120. Greijer, A.; de Jong, M.; Scheffer, G.; Shvarts, A.; van Diest, P.; van der Wall, E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol., 2005, 27, 43-49
121. Sullivan, R.; Graham, C.H. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol. Cancer Ther., 2009, 8, 1702-1713
122. Zeng, L.; Kizaka-Kondoh, S.; Itasaka, S.; Xie, X.; Inoue, M.; Tanimoto, K.; Shibuya, K.; Hiraoka, M. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci., 2007, 98, 1394-1401
123. Raspaglio, G.; Filippetti, F.; Prislei, S.; Penci, R.; De Maria, I.; Cicchillitti, L.; Mozzetti, S.; Scambia, G.; Ferlini, C. Hypoxia induces class III beta-tubulin gene expression by HIF-1[alpha] binding to its 3' flanking region. Gene, 2008, 409, 100-108
124. Kronblad, A.; Hedenfalk, I.; Nilsson, E.; Påhlman, S.; Landberg, G. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene, 2005, 24, 6835-6841
125. Wen, W.; Ding, J.; Sun, W.; Wu, K.; Ning, B.; Gong, W.; He, G.; Huang, S.; Ding, X.; Yin, P.; Chen, L.; Liu, Q.; Xie, W.; Wang, H. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res., 2010, 70, 2010-2019
126. Li, J.; Shi, M.; Cao, Y.; Yuan, W.; Pang, T.; Li, B.; Sun, Z.; Chen, L.; Zhao, R. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem. Biophys. Res. Commun., 2006, 342, 1341-1351
127. Huang, L.; Ao, Q.; Zhang, Q.; Yang, X.; Xing, H.; Li, F.; Chen, G.; Zhou, J.; Wang, S.; Xu, G.; Meng, L.; Lu, Y.; Ma, D. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxiainducible factor 1alpha. J. Cancer Res. Clin. Oncol., 2010, 136, 447-456
128. Martin, L.P.; Hamilton, T.C.; Schilder, R.J. Platinum Resistance: The Role of DNA Repair Pathways. Clin. Cancer Res., 2008, 14, 1291-1295
129. Marchesi, F.; Turriziani, M.; Tortorelli, G.; Avvisati, G.; Torino, F.; De Vecchis, L. Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol. Res., 2007, 56, 275-287
130. Zhang, N.; Zhang, H.; Xia, L.; Zheng, Y.; Yu, Y.; Zhu, Y.; Chen, G.; Di, W. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells. Cancer Lett., 2009, 278, 139-144
131. Sasabe, E.; Zhou, X.; Li, D.; Oku, N.; Yamamoto, T.; Osaki, T. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int. J. Cancer, 2007, 120, 268-277
132. Li, L.; Lin, X.; Shoemaker, A.; Albert, D.; Fesik, S.; Shen, Y. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin. Cancer Res., 2006, 12, 4747-4754
133. Engelman, J.; Jänne, P. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin. Cancer Res., 2008, 14, 2895-2899
134. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 316, 1039-1043
135. Youle, R.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol., 2008, 9, 47-59
136. Chen, N.; Chen, X.; Huang, R.; Zeng, H.; Gong, J.; Meng, W.; Lu, Y.; Zhao, F.; Wang, L.; Zhou, Q. CL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J. Biol. Chem., 2009, 284, 10004-10012
137. Piret, J.; Minet, E.; Cosse, J.; Ninane, N.; Debacq, C.; Raes, M.; Michiels, C. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem., 2005, 280, 9336-9344
138. Flamant, L.; Notte, A.; Ninane, N.; Raes, M.; Michiels, C. Antiapoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol. Cancer, 2010, 9, 191
139. Erler, J.; Cawthorne, C.; Williams, K.; Koritzinsky, M.; Wouters, B.; Wilson, C.; Miller, C.; Demonacos, C.; Stratford, I.; Dive, C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell Biol., 2004, 24, 2875-2889
140. Altieri, D. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer, 2008, 8, 61-70
141. Peng, X.; Karna, P.; Cao, Z.; Jiang, B.; Zhou, M.; Yang, L. Crosstalk between epidermal growth factor receptor and hypoxiainducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem., 2006, 281, 25903-25914
142. Chang, Q.; Qin, R.; Huang, T.; Gao, J.; Feng, Y. Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas, 2006, 32, 297-305
143. Hu, Y.; Kirito, K.; Yoshida, K.; Mitsumori, T.; Nakajima, K.; Nozaki, Y.; Hamanaka, S.; Nagashima, T.; Kunitama, M.; Sakoe, K.; Komatsu, N. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol. Cancer Ther., 2009, 8, 2329-2338
144. Pei, G.; Wu, C.; Lin, W. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alphamediated mechanism. Biochem. Biophys. Res. Commun., 2010, 391, 1274-1279
145. Mayes, P.; Campbell, L.; Ricci, M.; Plastaras, J.; Dicker, D.; El-Deiry, W. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol. Ther., 2005, 4, 1068-1074
146. Greijer, A.; van der Wall, E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J. Clin. Pathol., 2004, 57, 1009-1014
147. Okami, J.; Simeone, D.; Logsdon, C. Silencing of the hypoxiainducible cell death protein BNIP3 in pancreatic cancer. Cancer Res., 2004, 64, 5338-5346
148. Bacon, A.; Fox, S.; Turley, H.; Harris, A. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene, 2007, 26, 132-141
149. Mellor, H.; Harris, A. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev., 2007, 26, 553-566
150. Bellot, G.; Garcia-Medina, R.; Gounon, P.; Chiche, J.; Roux, D.; Pouysségur, J.; Mazure, N. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell Biol., 2009, 29, 2570-2581
151. Rapisarda, A.; Uranchimeg, B.; Scudiero, D.A.; Selby, M.; Sausville, E.A.; Shoemaker, R. H.; Melillo, G. Identification of Small Molecule Inhibitors of Hypoxia-inducible Factor 1 Transcriptional Activation Pathway. Cancer Res., 2002, 62, 4316-4324
152. Lee, K.; Zhang, H.; Qian, D.; Rey, S.; Liu, J.; Semenza, G. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA, 2009, 106, 17910-17915
153. Zhang, H.; Qian, D.; Tan, Y.; Lee, K.; Gao, P.; Ren, Y.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.; Liu, J.; Semenza, G. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA, 2008, 105, 19579-19586
154. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R.; Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res., 2004, 64, 1475-1482
155. Mabjeesh, N.J.; Escuin, D.; LaVallee, T.M.; Pribluda, V.S.; Swartz, G.M.; Johnson, M.S.; Willard, M.T.; Zhong, H.; Simons, J.W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003, 3, 363-375
156. Greenberger, L.; Horak, I.; Filpula, D.; Sapra, P.; Westergaard, M.; Frydenlund, H.; Albaek, C.; Schrøder, H.; Ørum, H. RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther., 2008, 7, 3598-3608
157. McCarty, M.; Barroso-Aranda, J.; Contreras, F. Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med. Hypotheses, 2010, 74, 789-797
158. Nakanishi, C.; Toi, M. Nuclear factor-[kappa]B inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer, 2005, 5, 297-309
159. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer, 2004, 4, 349-360
160. Shin, D.H.; Chun, Y.-S.; Lee, D.S.; Huang, L.E.; Park, J.-W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood, 2008, 111, 3131-3136
161. Birle, D.C.; Hedley, D.W. Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors. Cancer Res., 2007, 67, 1735-1743
162. Nardinocchi, L.; Puca, R.; Sacchi, A.; D'Orazi, G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol. Cancer, 2009, 8, 1
163. Nardinocchi, L.; Puca, R.; Sacchi, A.; Rechavi, G.; Givol, D.; D'Orazi, G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One, 2009, 4, e6819
164. Li, X.; Lu, Y.; Liang, K.; Pan, T.; Mendelsohn, J.; Fan, Z. Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the antiâ"epidermal growth factor receptor monoclonal antibody cetuximab. Mol. Cancer Ther., 2008, 7, 1207-1217
165. Pore, N.; Jiang, Z.; Gupta, A.; Cerniglia, G.; Kao, G. D.; Maity, A. EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1 -Independent and HIF-1 - Dependent Mechanisms Cancer Res., 2006, 66, 3197-3204
166. Cerniglia, G.; Pore, N.; Tsai, J.; Schultz, S.; Mick, R.; Choe, R.; Xing, X.; Durduran, T.; Yodh, A.; Evans, S.; Koch, C.; Hahn, S.; Quon, H.; Sehgal, C.; Lee, W.; Maity, A. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One, 2009, 4, e6539
167. Mabuchi, S.; Altomare, D.A.; Cheung, M.; Zhang, L.; Poulikakos, P.I.; Hensley, H.H.; Schilder, R.J.; Ozols, R.F.; Testa, J.R. RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model. Clin. Cancer Res., 2007, 13, 4261-4270
168. Hudson, C.; Liu, M.; Chiang, G.; Otterness, D.; Loomis, D.; Kaper, F.; Giaccia, A.; Abraham, R. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol., 2002, 22, 7004-7014
169. Cho, D.C.; Cohen, M.B.; Panka, D.J.; Collins, M.; Ghebremichael, M.; Atkins, M.B.; Signoretti, S.; Mier, J.W. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clin. Cancer Res., 2010, 16, 3628-3638
170. Shin, H.; Cho, C.; Kim, T.; Park, J. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem. Biophys. Res. Commun., 2010
171. Beppu, K.; Nakamura, K.; Linehan, W.; Rapisarda, A.; Thiele, C. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res., 2005, 65, 4775-4781
172. Fotsis, T.; Zhang, Y.; Pepper, M.; Adlercreutz, H.; Montesano, R.; Nawroth, P.; Schweigerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 1994, 368, 237-239
173. Escuin, D.; Kline, E.; Giannakakou, P. Both microtubulestabilizing and microtubule-destabilizing drugs inhibit hypoxiainducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res., 2005, 65, 9021-9028
174. Welsh, S.; Williams, R.; Kirkpatrick, L.; Paine-Murrieta, G.; Powis, G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1. Mol. Cancer Ther., 2004, 3, 233-244
175. Koh, M.; Spivak-Kroizman, T.; Venturini, S.; Welsh, S.; Williams, R.; Kirkpatrick, D.; Powis, G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther., 2008, 7, 90-100
176. Zhang, Q.; Tang, X.; Lu, Q.Y.; Zhang, Z.F.; Brown, J.; Le, A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxiainducible factor-1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther., 2005, 4, 1465-1474
177. Zhang, Q.; Tang, X.; Lu, Q.; Zhang, Z.; Rao, J.; Le, A.D. Green tea extract and (-)epigallocatechin-3-gallate inhibit hypoxia-and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther., 2006, 5, 1227-1238
178. Lee, K.; Kang, J.; Park, S.; Jin, Y.; Chung, K.; Kim, H.; Kang, M.; Lee, M.; Song, K.; Yang, E.; Lee, J.; Won, M. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem. Pharmacol., 2010, 80, 982-989
179. Kung, A.; Zabludoff, S.; France, D.; Freedman, S.; Tanner, E.; Vieira, A.; Cornell-Kennon, S.; Lee, J.; Wang, B.; Wang, J.; Memmert, K.; Naegeli, H.; Petersen, F.; Eck, M.; Bair, K.; Wood, A.; Livingston, D. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 2004, 6, 33-43
180. Kong, D.; Park, E.J.; Stephen, A.G.; Calvani, M.; Cardellina, J.H.; Monks, A.; Fisher, R.J.; Shoemaker, R.H.; Melillo, G. Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity. Cancer Res., 2005, 65, 9047-9055
181. Vlaminck, B.; Toffoli, S.; Ghislain, B.; Demazy, C.; Raes, M.; Michiels, C. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J., 2007, 274, 5533-5542
182. Lee, Y.; Lim, J.; Chun, Y.; Moon, H.; Lee, M.; Huang, L.; Park, J. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis, 2009, 30, 1768-1775
183. Li, S.; Shin, D.; Chun, Y.; Lee, M.; Kim, M.; Park, J. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIHdependent p300 dissociation from HIF-1{alpha}. Mol. Cancer Ther., 2008, 7, 3729-3738
184. Sun, H.; Liu, Y.; Huang, Y.; Pan, S.; Huang, D.; Guh, J.; Lee, F.; Kuo, S.; Teng, C. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene, 2007, 26, 3941-3951
185. Kim, H.; Yeo, E.; Chun, Y.; Park, J. A domain responsible for HIF- 1alpha degradation by YC-1, a novel anticancer agent. Int. J. Oncol., 2006, 29, 255-260
186. Lee, K.; Qian, D.; Rey, S.; Wei, H.; Liu, J.; Semenza, G. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA, 2009, 106, 2353-2358.